Telephone support to rural and remote patients with heart failure: the Chronic Heart Failure Assessment by Telephone (CHAT) study. Cardiovascular Therapeutics. 2013; 31(4):230-237 184. Krum H, Shi H, Pitt B, McMurray J, Swedberg K, Veldhuisen DJ et al. Clinical benefit of eplerenone in patients with mild symptoms of systolic heart failure already receiving optimal best practice background drug therapy: analysis of the EMPHASIS-HF study. Circulation: 185. Krupicka J, Janota T, Hradec J. Optimalization of heart failure therapy guided by plasma BNP concentrations. European Heart Journal. 2010; 31:859-860 186. Ky B, French B, Levy WC, Sweitzer NK, Fang JC, Wu AH et al. Multiple biomarkers for risk prediction in chronic heart failure. Circulation: Heart Failure. 2012; 5(2):183-90 187. LaDonna KA, Bates J, Tait GR, McDougall A, Schulz V, Lingard L. 'Who is on your health-care team?'Asking individuals with heart failure about care team membership and roles. Health 188. Lainchbury JG, Troughton RW, Frampton CM, Yandle TG, Hamid A, Nicholls MG et al. NT- proBNP-guided drug treatment for chronic heart failure: design and methods in the "BATTLESCARRED" trial. European Journal of Heart Failure. 2006; 8(5):532-8 189. Lainchbury JG, Troughton RW, Strangman KM, Frampton CM, Pilbrow A, Yandle TG et al. N- terminal pro-B-type natriuretic peptide-guided treatment for chronic heart failure: results from the BATTLESCARRED (NT-proBNP-Assisted Treatment To Lessen Serial Cardiac Readmissions and Death) trial. Journal of the American College of Cardiology. 2009; 55(1):53- 190. Laramee AS, Levinsky SK, Sargent J, Ross R, Callas P. Case management in a heterogeneous congestive heart failure population: a randomized controlled trial. Archives of Internal Chronic Heart Failure Reference list NICE 2018. All rights reserved. Subject to Notice of rights. ISBN: 978-1-4731-3093-7 191. Laramee P, Wonderling D, Swain S, Al-Mohammad A, Mant J. 